MedTrace Logo

Study of AMV564 in Patients With AML

NCT03144245 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-10-12

No results posted yet for this study

Summary

This is a first in human, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of AMV564.

Conditions

Interventions

BIOLOGICAL

AMV564

AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing

COMBINATION_PRODUCT

AMV564 in combination with pembrolizumab

AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days

Sponsors & Collaborators

  • Amphivena Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Chun, MD · Amphivena Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-20
Primary Completion
2020-07-21
Completion
2020-11-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03144245 on ClinicalTrials.gov